Acquired pure red cell aplasia in a hemodialyzed patient

A 68‐year‐old male had end‐stage renal disease secondary to hypertension. He was placed on chronic dialytic therapy and was given recombinant human erythropoietin (epoetin) for renal anemia. One month later, rapidly progressing anemia was noted. The anemia was unresponsive to maximal doses of epoeti...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of urology Vol. 10; no. 10; pp. 550 - 553
Main Authors TANUMA, YASUSHI, YOKOO, AKIFUMI, TAKASHIMA, HIDENORI
Format Journal Article
LanguageEnglish
Published Melbourne, Australia Blackwell Science Pty 01.10.2003
Subjects
Aged
Erythropoietin - adverse effects
hemodialysis
Humans
Male
pure red cell aplasia
recombinant human erythropoietin
Recombinant Proteins
Red-Cell Aplasia, Pure - chemically induced
Renal Dialysis
Online AccessGet full text

Cover

More Information
Summary:A 68‐year‐old male had end‐stage renal disease secondary to hypertension. He was placed on chronic dialytic therapy and was given recombinant human erythropoietin (epoetin) for renal anemia. One month later, rapidly progressing anemia was noted. The anemia was unresponsive to maximal doses of epoetin and the patient soon became transfusion‐dependent. Erythroid hypoplasia was demonstrated by bone marrow biopsy. A detailed search for the cause of the erythroblastopenia revealed nothing. A diagnosis of acquired pure red cell aplasia was made. The use of immunosuppressive agents improved the patient's symptoms and laboratory data. Antibodies for erythropoietin (EPO) were negative after the treatment. It is suggested that patients with EPO‐resistant anemia with no obvious etiology should be examined for underlying hematologic disorders.
ISSN:0919-8172
1442-2042
DOI:10.1046/j.1442-2042.2003.00672.x